1. Membrane Transporter/Ion Channel
  2. Sodium Channel

Eleclazine hydrochloride (Synonyms: GS 6615 hydrochloride)

Cat. No.: HY-16738A Purity: 99.47%
Data Sheet SDS Handling Instructions

Eleclazine hydrochloride is a novel late Na+ current inhibitor with IC50 value of 0.7 uM.

For research use only. We do not sell to patients.
Eleclazine hydrochloride Chemical Structure

Eleclazine hydrochloride Chemical Structure

CAS No. : 1448754-43-5

Size Price Stock Quantity
10 mM * 1 mL in DMSO $348 In-stock
1 mg $150 In-stock
5 mg $350 In-stock
10 mg $550 In-stock
25 mg $1100 In-stock
50 mg $1600 In-stock
100 mg $2300 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Eleclazine hydrochloride is a novel late Na+ current inhibitor with IC50 value of 0.7 uM. target: Na+ current. IC50: 0.7 uM. In vitro: Eleclazine hydrochloride inhibits ATX-II enhanced late INa in ventricular myocytes, shorten the ATX-II induced prolongation of APD, MAPD, QT interval, and decreased spatiotemporal dispersion of repolarization and ventricular arrhythmias. Inhibition by GS-6615 of ATX-II enhanced late INa is strongly correlated with shortening of myocyte APD and isolated heart MAPD[1]. Selective inhibition of cardiac late INa with eleclazine hydrochloride confers dual protection against vulnerability to ischemia-induced AF and reduces atrial and ventricular repolarization abnormalities before and during adrenergic stimulation without negative inotropic effects. [2]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02300558 Gilead Sciences Long QT Syndrome Type 3 December 17, 2014 Phase 3
NCT02441829 Gilead Sciences Long QT Syndrome May 2015 Phase 1
NCT02412098 Gilead Sciences Long QT Syndrome March 2015 Phase 1
NCT02291237 Gilead Sciences Hypertrophic Cardiomyopathy February 5, 2015 Phase 2|Phase 3
NCT02365506 Gilead Sciences LQT2 Syndrome July 2015 Phase 1
NCT02104583 Gilead Sciences Ventricular Arrhythmia September 2014 Phase 2
NCT02377336 Gilead Sciences Ischemic Heart Disease May 2015 Phase 2
NCT01847391 Gilead Sciences Ischemic Heart Disease May 2013 Phase 1
NCT02365532 Gilead Sciences Long QT Syndrome February 2015 Phase 1
NCT01849003 Gilead Sciences Long QT Syndrome May 2013 Phase 1
View MoreCollapse
References
Molecular Weight

451.83

Formula

C₂₁H₁₇ClF₃N₃O₃

CAS No.

1448754-43-5

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Eleclazine hydrochloride
Cat. No.:
HY-16738A
Quantity: